



Published in final edited form as:

*Microbes Infect.* 2021 ; 23(2-3): 104777. doi:10.1016/j.micinf.2020.11.004.

## DNA alternate polymerase PolB mediates inhibition of type III secretion in *Pseudomonas aeruginosa*

Shubham Chakravarty, Layla Ramos-Hegazy, Abigail Gasparovic, Gregory G. Anderson\*

Department of Biology, Indiana University Purdue University Indianapolis, Indianapolis, IN, USA

### Abstract

Opportunistic pathogen *Pseudomonas aeruginosa* uses a variety of virulence factors to cause acute and chronic infections. We previously found that alternate DNA polymerase gene *polB* inhibits *P. aeruginosa* pyocyanin production. We investigated whether *polB* also affects T3SS expression. *polB* overexpression significantly reduced T3SS transcription and repressed translation of the master T3SS regulator ExsA, while not affecting *exsA* mRNA transcript abundance. Further, *polB* does not act through previously described genetic pathways that post-transcriptionally regulate ExsA. Our results show a novel T3SS regulatory component which may lead to development of future drugs to target this mechanism.

### Keywords

*Pseudomonas aeruginosa*; Type III secretion; stress

## 1. Introduction

*Pseudomonas aeruginosa* is a deadly pathogen that can be acquired from the environment or hospitals and can cause a vast array of infections, including keratitis, acute pneumonia, bacteremia, and burn infections [1]. One of the worst manifestations of *P. aeruginosa* infections is in CF lungs where it causes acute and chronic infections and is nearly impossible to eradicate due to its intrinsic antimicrobial resistance and ability to form biofilms [2, 3]. The versatility and severity of *P. aeruginosa* infections is attributed to the many virulence factors that are used to destroy host cells, including pyoverdine, pyocyanin, and the type III secretion system (T3SS) [4]. During the acute phase of infection, *P. aeruginosa* uses T3SS, a macromolecular syringe-like structure, to inject toxins that ultimately destroy the host cell. The T3SS effector toxins ExoU, ExoS, ExoT, and ExoY induce cell death by disrupting the host cell cytoskeleton, cell membrane, and cAMP levels thereby enhancing disease severity [1].

\*To whom correspondence should be addressed: Indiana University Purdue University Indianapolis, Department of Biology, 723 West Michigan St., SL 320, Indianapolis, IN 46202, Tel 317-278-3896, Fax 317-274-2846, ga2@iupui.edu.

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

<sup>5</sup>-Conflict of Interest

The authors state that they have no conflicts of interest.

Regulation of T3SS activity consists of complicated genetic networks that tightly regulate this critical virulence factor. The T3SS regulon in *P. aeruginosa* contains ~40 genes that are all controlled by the master regulatory protein ExsA [5]. During non-inducing conditions, ExsA is bound and inhibited by ExsD, the anti-activator, while ExsC is inhibited by ExsE [5]. Low calcium concentration, the presence of serum, and host cell contact are factors known to increase ExsA levels and initiate T3SS expression [5]. Activation of this system leads to a partner-switching mechanism where ExsD binds to the anti-anti-activator ExsC, therefore liberating ExsA to bind to T3SS promoter sites and initiate transcription [5]. It is important to note that ExsA also regulates its own transcription, via the  $P_{\text{exsCEBA}}$  promoter site, resulting in a positive feedback loop [5]. Regulation of *exsA* transcriptional activation is also stimulated by Vfr, a global regulator of virulence factor expression that is controlled by cAMP concentrations [6]. Additionally, *exsA* expression is post-transcriptionally regulated by the RNA binding protein RsmA. RsmA levels in the cell are in turn regulated by small non-coding RNAs RsmY and RsmZ, which bind to this protein and titrate it away from its mRNA targets [7]. Environmental factors also influence ExsA inhibition. For example, the magnesium transporter MgtE can inhibit *exsA* post-transcriptional activity via inhibition of RsmA through RsmY and RsmZ [8]. Additionally, stress response genes such as the alternative sigma factor AlgU (AltT) has been shown to downregulate T3SS expression [9]. Overall, a general hallmark of T3SS gene expression is that it is downregulated under stressful conditions [9].

Previously, our laboratory found that mutation of *polB* (*PA14\_40120*), encoding a stress-induced DNA polymerase, decreases biofilm formation and increases cytotoxicity by 70% compared to wild type by enhancing pyocyanin levels [10]. While the full impact of PolB on *P. aeruginosa* behavior is unclear, one study showed that it is homologous to the DNA repair system Pol II in *Escherichia coli* and is activated during DNA damage [11]. Considering that conditions for T3SS inhibition and PolB activation match (*i.e.* stress), we hypothesized that PolB could also inhibit T3SS activity. This study shows that *polB* overexpression leads to a decrease in T3SS promoter activity via post-transcriptional inhibition of the T3SS activator ExsA. This inhibition is *exsD* and *rsmYZ* independent, suggesting an alternate post-transcriptional ExsA inhibitory pathway.

## 2. Materials and Methods

### 2.1 Bacterial strains and culture conditions

Experiments were carried out in *P. aeruginosa* strains PA14 and PA103 [8]. Strains and plasmids are described in Table 1. Expression of *polB* was performed by transforming the strains with plasmid *ppolB*, containing the *polB* gene downstream from the  $P_{\text{araBAD}}$  promoter on vector pMQ72 [10]. This plasmid is maintained at high copy number in *P. aeruginosa* [12], and induction of the  $P_{\text{araBAD}}$  promoter is not required for expression in *P. aeruginosa* [10]. Plasmids were maintained in *E. coli* S17 [13] cultured on LB agar plates or LB containing 10  $\mu\text{g}/\text{mL}$  gentamicin. Isolation of the plasmid from *E. coli* was accomplished by using the QIAprep spin miniprep kit (Qiagen) according to the manufacturer's instructions, and plasmids were transformed into *P. aeruginosa* strains using electroporation. Transformed *P. aeruginosa* strains were cultured on Vogel Bonner minimal (VBM) medium

plates with 60 µg/mL gentamicin [14]. Plasmid presence was confirmed by PCR primers p729 and p730 [15].

## 2.2 β-Galactosidase assays

Strains were grown to an OD<sub>600</sub> of 1.0 and β-galactosidase activity was measured as previously described [14], using T3SS transcriptional reporters PA14 P<sub>exsD</sub>-*lacZ* and PA103 P<sub>exsD</sub>-*lacZ* (each containing the *exsD* promoter fused to a promoterless *lacZ*) [13, 14] and ExsA translational reporter PA103 P<sub>lacUV5</sub>-*exsCEBA*'-'*lacZ* (containing *lacZ* fused in-frame at *exsA* codon 77) [14]. The substrate orthonitrophenyl-β-D-galactopyranoside (ONPG) was used in all β-galactosidase assays involving transcriptional reporters. For translational reporters, chlorophenol red β-D-galactopyranoside (CPRG) was used as the substrate. 2mM EGTA was added in all experiments to induce T3SS activity [8]. Data were normalized to the average pMQ72 value (as 100%); there was very little variation in pMQ72 samples, and thus error bars are very small.

## 2.3 RNA isolation and qRT-PCR

Strains were cultured as described above and 1 mL of culture was collected at an OD<sub>600</sub> of 1. Cells were pelleted and washed with 1X PBS and RNA was isolated using the RNeasy Plus Kit (Qiagen) according to the manufacturer's instructions. Modifications were made to the protocol as described earlier [15]. cDNA was synthesized using the Superscript III First-Strand Synthesis for RT-PCR kit (Invitrogen; Eugene, OR), according to the manufacturer's instructions. DNA contamination was tested by performing cDNA synthesis in the absence of reverse transcriptase; this control indicated the absence of DNA in our RNA samples (not shown). Quantitative Real-time-PCR (qRT-PCR) was performed as previously reported using the LightCycler 480 Instrument (Roche) [15]. Primers *exsARTfor* and *exsARTrev* [8] were used to amplify *exsA* from nucleotides 436 to 676. Samples were normalized to the *fbp* transcript using primers PA5110for and PA5110rev, as described [15]. For semiquantitative RT-PCR, cDNA was subjected to standard PCR with primer pairs QpolBfor/QpolBrev and P5110for/5110rev [10], with the following thermocycler conditions: 95°C 5 min., 25X(95°C 1 min., 55°C 30 sec., 72°C 1 min.), 72°C 10 min. PCR reaction was then electrophoresed through a 1% agarose gel.

## 2.4 Strain construction of PA103 *exsD*

Isogenic *exsD* deletion was carried out using plasmid pSMC296, as previously described [16]. This plasmid was maintained in *E. coli* S17 and conjugated into PA103 P<sub>exsD</sub>-*lacZ*. Exoconjugants were selected on LB plates containing 80 µg/mL gentamicin and 20 µg/mL nalidixic acid. Isolated colonies were grown overnight in LB and then plated on LB agar containing 10% sucrose to select for excision of the plasmid. Deletion mutants were confirmed using primers *ExsDfor* (GCGACATGAGCATCGTCGAC) and *ExsDrev* (CAGCAACAGGACGCTCTGTC).

### 3. Results

#### 3.1 *polB* inhibits T3SS activity in PA14 and PA103

$\beta$ -galactosidase assays were used to measure transcriptional activity of T3SS in PA14  $P_{\text{exsD}}\text{-lacZ}$  and PA103  $P_{\text{exsD}}\text{-lacZ}$ . Though ExsD can inhibit T3SS activation through protein-protein interactions, its gene is the first in one of the longest T3SS operons, and the  $P_{\text{exsD}}\text{-lacZ}$  construct has been used extensively to report T3SS transcriptional activation [5, 6, 8, 14, 16]. In PA14, *polB* overexpression resulted in a 20% reduction in  $\beta$ -galactosidase activity at the T3SS promoter site compared to PA14 with empty control vector pMQ72 (Fig. 1A). Similarly, in PA103, a strain with hyperactive T3SS activity, *polB* overexpression led to 45% less  $\beta$ -galactosidase activity from the T3SS promoter site than PA103 with empty control vector (Fig. 1B). Importantly, expression from *ppolB* led to dramatic increase in *polB* transcript levels, compared to strains with vector control (Fig. 1C).

#### 3.2 *polB* inhibits T3SS activity via post-transcriptional regulation of *exsA*

To determine the mechanism by which *polB* inhibits *exsA* activity, qRT-PCR was used to measure relative *exsA* transcript levels. Compared to PA103 with empty vector, *polB* overexpression did not lower *exsA* transcript abundance (Fig. 2A). To measure *exsA* translation,  $\beta$ -galactosidase activity was determined from a PA103  $P_{\text{lacUV5-exsCEBA}'}\text{-lacZ}$  *exsA* translational reporter [14]. ExsA translational activity was significantly reduced when *polB* was overexpressed in PA103  $P_{\text{lacUV5-exsCEBA}'}\text{-lacZ}$  (Fig. 2B). These results indicate that *polB* expression inhibits ExsA synthesis by affecting *exsA* translation while not impacting *exsA* mRNA turnover.

#### 3.3 *polB* bypasses the *rsmYZ* and *exsD* mediated inhibition of ExsA

Post-transcriptional inhibition of ExsA is mediated through the RsmYZ/RsmA pathway. RsmA can be sequestered by RsmYZ, leading to decreased ExsA translation. However, overexpression of *polB* in PA103 *rsmYZ* with the T3SS  $P_{\text{exsD}}\text{-lacZ}$  transcriptional reporter still led to inhibition of T3SS activity (Fig. 3A). To investigate another potential effect of *polB* on ExsA post-transcriptional activity, *exsD* was isogenically deleted in PA103 containing the T3SS  $P_{\text{exsD}}\text{-lacZ}$  transcriptional reporter. ExsD binds and sequesters ExsA, so *exsD* strains exhibit highly active T3SS [5, 16]. When *polB* was overexpressed in the PA103 *exsD* strain, T3SS transcriptional activity was still inhibited (Fig. 3B). This data further indicates that *polB* acts on ExsA synthesis, rather than acting through functional ExsA activators/inhibitors.

### 4. Discussion

Virulence in *P. aeruginosa* is tightly regulated. It is not surprising that 8% of the *P. aeruginosa* genome codes for multiple regulatory genes and pathways, including those that respond to various environmental signals [17]. Some of these regulatory mechanisms include downregulation of virulence factors in response to stress, most likely as a survival mechanism for this microorganism. For example, the alternative sigma factor AlgU (AlgT), which is expressed during chronic infection state and oxidative stress, downregulates T3SS expression [9, 18]. Similarly, *P. aeruginosa* isolates from CF patients exhibit a high mucoid

phenotype due to mutations in *mucA*, further enabling this microorganism to survive and cause chronic infections [19]. Furthermore, metabolic dysregulation and nutritional stress also inhibit T3SS [20]. This current study reveals a novel role for stress-related gene *polB* in downregulating T3SS expression. *polB* encodes an alternate DNA polymerase that is activated during DNA damage. Prior research showed that *polB* mutation decreased biofilm formation and increased cytotoxicity through stimulation of pyocyanin levels [10]. Here, we found that overexpression of *polB* in *trans* showed a downregulation of T3SS activity in PA14 and PA103 (Fig. 1) [14]. It is important to note that deletion of *polB* in PA14 and PA103 had no effect on T3SS expression (not shown), most likely because *polB* has minimal expression under homeostatic conditions (Fig. 1C). Thus, we used plasmid based *polB* expression as a surrogate to mimic what happens under stressful conditions when *polB* expression is high. It is possible that use of antibiotics to maintain plasmids could confer a level of intrinsic stress to the system, though we found very little *polB* transcription in pMQ72 samples, which were also treated with antibiotics (Fig. 1C). In contrast, transforming *P. aeruginosa* with *ppolB* resulted in high *polB* transcript levels (Fig. 1C).

This study highlights an important *exsA* inhibitory pathway. *polB*-mediated downregulation of T3SS activity is due to post-transcriptional ExsA inhibition (Fig. 2). The exact mechanism of this inhibition is unclear. Though RsmY and RsmZ inhibit ExsA translation [10, 14], ExsA inhibition was still seen in the *rsmYZ* strain (Fig. 3). ExsD also failed to show an effect in this process (Fig. 3). Because *polB* inhibited translation (Fig. 2), it likely does not additionally influence *exsA* activity through Vfr or the autoregulatory transcriptional pathway. Due to PolB's role in error prone DNA replication during stress [11], and the accumulation of mutations in *P. aeruginosa* during prolonged stress exposure [9, 21, 22], we speculate that PolB-induced mutation during stress could be activating expression of regulatory factors that repress ExsA translation, or it could be inhibiting expression of genes that encode ExsA translational activators. It would be interesting in future experiments to test whether *polB* inhibits *exsA* post-transcriptionally through PtrB, which inhibits T3SS in response to DNA damage [23]. Alternatively, *polB* might be affecting expression of some upstream *exsA* regulators.

Many CF *P. aeruginosa* isolates exhibit non-functioning DNA repair mechanisms, thereby enhancing the genetic mutations in a stressful environment [24, 25]. These mutations presumably increase survival under these conditions. By understanding how *P. aeruginosa* regulates virulence in stress, we can design better therapeutics to fight these infections.

## Acknowledgments


We thank J. Pugsley and M. Cripe for helpful conversations and insights. We also thank T. Yahr for sharing transcriptional and translational constructs and G. O'Toole for sharing pSMC296. This work was supported by 16GRNT30230012 from the American Heart Association and 1R03AR068724-01 from the National Institutes of Health to G.G.A.

## 7. References

- [1]. Scheetz MH, Hoffman M, Bolon MK, Schulert G, Estrellado W, Baraboutis IG, et al. Morbidity associated with *Pseudomonas aeruginosa* bloodstream infections. *Diagn Microbiol Infect Dis* 2009;64:311–9. [PubMed: 19345039]

- [2]. Moore JE, Mastoridis P. Clinical implications of *Pseudomonas aeruginosa* location in the lungs of patients with cystic fibrosis. *Journal of Clinical Pharmacy & Therapeutics* 2017;42:259–67. [PubMed: 28374433]
- [3]. Tolker-Nielsen T *Pseudomonas aeruginosa* biofilm infections: from molecular biofilm biology to new treatment possibilities. *APMIS. Supplementum* 2014;1–51.
- [4]. Malhotra S, Hayes D Jr., Wozniak DJ. Cystic fibrosis and *Pseudomonas aeruginosa*: the host-microbe interface. *Clin Microbiol Rev* 2019;32.
- [5]. Williams McMackin EA, Djapgne L, Corley JM, Yahr TL. Fitting pieces into the puzzle of *Pseudomonas aeruginosa* type III secretion system gene expression. *J Bacteriol* 2019;201.
- [6]. Fuchs EL, Brutinel ED, Jones AK, Fulcher NB, Urbanowski ML, Yahr TL, et al. The *Pseudomonas aeruginosa* Vfr regulator controls global virulence factor expression through cyclic AMP-dependent and -independent mechanisms. *J Bacteriol* 2010;192:3553–64. [PubMed: 20494996]
- [7]. Brencic A, McFarland KA, McManus HR, Castang S, Mogno I, Dove SL, et al. The GacS/GacA signal transduction system of *Pseudomonas aeruginosa* acts exclusively through its control over the transcription of the RsmY and RsmZ regulatory small RNAs. *Mol Microbiol* 2009;73:434–45. [PubMed: 19602144]
- [8]. Chakravarty S, Melton CN, Bailin A, Yahr TL, Anderson GG. *Pseudomonas aeruginosa* magnesium transporter MgtE inhibits type III secretion system gene expression by stimulating *rsmYZ* transcription. *J Bacteriol* 2017;199.
- [9]. Jones AK, Fulcher NB, Balzer GJ, Urbanowski ML, Pritchett CL, Schurr MJ, et al. Activation of the *Pseudomonas aeruginosa* AlgU regulon through *mucA* mutation inhibits cyclic AMP/Vfr signaling. *J Bacteriol* 2010;192:5709–17. [PubMed: 20817772]
- [10]. Alshalchi SA, Anderson GG. Involvement of stress-related genes *polB* and *PA14\_46880* in biofilm formation of *Pseudomonas aeruginosa*. *Infect Immun* 2014;82:4746–57. [PubMed: 25156741]
- [11]. Kivisaar M Mechanisms of stationary-phase mutagenesis in bacteria: mutational processes in *pseudomonads*. *FEMS Microbiol Lett* 2010;312:1–14. [PubMed: 20572869]
- [12]. Shanks RM, Caiazza NC, Hinsa SM, Toutain CM, O'Toole GA. *Saccharomyces cerevisiae*-based molecular tool kit for manipulation of genes from Gram-negative bacteria. *Appl Environ Microbiol* 2006;72:5027–36. [PubMed: 16820502]
- [13]. Moreau-Marquis S, Redelman CV, Stanton BA, Anderson GG. Co-culture models of *Pseudomonas aeruginosa* biofilms grown on live human airway cells. *J Vis Exp* 2010.
- [14]. Intile PJ, Diaz MR, Urbanowski ML, Wolfgang MC, Yahr TL. The AlgZR two-component system recalibrates the RsmAYZ posttranscriptional regulatory system to inhibit expression of the *Pseudomonas aeruginosa* type III secretion system. *J Bacteriol* 2014;196:357–66. [PubMed: 24187093]
- [15]. Redelman CV, Chakravarty S, Anderson GG. Antibiotic treatment of *Pseudomonas aeruginosa* biofilms stimulates expression of the magnesium transporter gene *mgtE*. *Microbiology* 2014;160:165–78. [PubMed: 24162608]
- [16]. Anderson GG, Yahr TL, Lovewell RR, O'Toole GA. The *Pseudomonas aeruginosa* magnesium transporter MgtE inhibits transcription of the type III secretion system. *Infect Immun* 2010;78:1239–49. [PubMed: 20028803]
- [17]. Rodrigue A, Quentin Y, Lazdunski A, Méjean V, Foglino M. Cell signalling by oligosaccharides. Two-component systems in *Pseudomonas aeruginosa*: why so many? *Trends Microbiol* 2000;8:498–504. [PubMed: 11121759]
- [18]. Mathee K, Ciofu O, Sternberg C, Lindum PW, Campbell JIA, Jensen P, et al. Mucoid conversion of *Pseudomonas aeruginosa* by hydrogen peroxide: a mechanism for virulence activation in the cystic fibrosis lung. *Microbiology* 1999;145:1349–57. [PubMed: 10411261]
- [19]. Folkesson A, Jelsbak L, Yang L, Johansen HK, Ciofu O, Høiby N, et al. Adaptation of *Pseudomonas aeruginosa* to the cystic fibrosis airway: an evolutionary perspective. *Nat Rev Microbiol* 2012;10:841–51. [PubMed: 23147702]
- [20]. Rietsch A, Wolfgang MC, Mekalanos JJ. Effect of metabolic imbalance on expression of type III secretion genes in *Pseudomonas aeruginosa*. *Infect Immun* 2004;72:1383. [PubMed: 14977942]


- [21]. Oliver A, Baquero F, Blazquez J. The mismatch repair system (*mutS*, *mutL* and *uvrD* genes) in *Pseudomonas aeruginosa*: molecular characterization of naturally occurring mutants. *Mol Microbiol* 2002;43:1641–50. [PubMed: 11952911]
- [22]. Oliver A, Sanchez JM, Blazquez J. Characterization of the GO system of *Pseudomonas aeruginosa*. *FEMS Microbiol Lett* 2002;217:31–5. [PubMed: 12445642]
- [23]. Wu W, Jin S. PtrB of *Pseudomonas aeruginosa* suppresses the type III secretion system under the stress of DNA damage. *J Bacteriol* 2005;187:6058. [PubMed: 16109947]
- [24]. Mandsberg LF, Ciofu O, Kirkby N, Christiansen LE, Poulsen HE, Høiby N. Antibiotic resistance in *Pseudomonas aeruginosa* strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. *Antimicrob Agents Chemother* 2009;53:2483. [PubMed: 19332676]
- [25]. Winsor GL, Lam DKW, Fleming L, Lo R, Whiteside MD, Yu NY, et al. Pseudomonas Genome Database: improved comparative analysis and population genomics capability for *Pseudomonas* genomes. *Nucleic Acids Res* 2010;39:D596–D600. [PubMed: 20929876]




**Figure 1. Overexpression of *polB* inhibits T3SS gene expression.**

B-galactosidase activity was measured in (A) PA14  $P_{\text{exsD}}\text{-lacZ}$  and (B) PA103  $P_{\text{exsD}}\text{-lacZ}$ , compared to empty control vector (pMQ72). The results are representative of three independent experiments carried out in triplicate ( $n = 3$ ) and error bars represent standard deviation. Error bars of pMQ72 samples are present but very small. \* $p < 0.05$  compared to pMQ72. (C) Semiquantitative analysis of *polB* transcript levels in 3 independent samples of PA103 pMQ72 and PA103 *ppolB*. *fbp* is our control transcript. All images were taken from the same agarose gel, with no alteration of brightness or contrast.





**Figure 2. *polB* overexpression decreases *exsA* translation, but not transcript abundance.** Overexpression of *polB* (A) does not affect *exsA* transcript abundance in PA103 but (B) inhibits *exsA* translation compared to empty control vector (pMQ72) in PA103 with the  $P_{lacUV5}$ -*exsCEBA*'-'*lacZ exsA* translational reporter. The results are representative of three independent experiments carried out in triplicate (n = 3) and error bars represent standard deviation. Error bars of pMQ72 sample in (B) are present but very small. \*p < 0.05 compared to PA103 pMQ72.



**Figure 3. *polB* bypasses the *rsmYZ* and *exsD* mediated inhibition of T3SS.**

Inhibition of 3SS activity is present in (A) PA103  $\Delta rsmYZ$  and (B) PA103  $\Delta exsD$  when *polB* is overexpressed compared to empty control vector (pMQ72). The results are representative of three independent experiments carried out in triplicate (n = 3) and error bars represent standard deviation. Error bars of pMQ72 samples are present but very small. \*p < 0.05 compared to pMQ72.

**Table 1.**

Stains and plasmids used in this study

<b>Strains</b>	<b>Relevant Characteristics</b>	<b>Source</b>
PA14	Wild type	[8]
PA103	Wild type	[8]
PA14 P <sub>exsD</sub> -lacZ	T3SS transcriptional reporter	[14]
PA103 P <sub>exsD</sub> -lacZ	T3SS transcriptional reporter	[14]
PA103 P <sub>exsD</sub> -lacZ <i>rsmYZ</i>	Transcriptional reporter, isogenic deletion of <i>rsmYZ</i>	[8]
PA103 P <sub>exsD</sub> -lacZ <i>exsD</i>	Transcriptional reporter, isogenic deletion of <i>exsD</i>	This study
PA103 P <sub>lacUV5-exsCEBA'-lacZ</sub>	ExsA translational reporter	[14]
<b>Plasmids</b>		
pSMC296	<i>exsD</i> isogenic deletion	[16]
pMQ72	Empty control vector	[12]
ppolB	<i>polB</i> expression plasmid	[10]